Human heat shock protein-specific cytotoxic T lymphocytes display potent antitumour immunity in multiple myeloma

British Journal of Haematology

Volumn 166, Issue 5, 2014, Pages 690-701

  Li, Rong ^a   Qian, Jianfei ^b,c   Zhang, Wenhao ^a   Fu, Weijun ^a   Du, Juan ^a   Jiang, Hua ^a   Zhang, Hui ^a   Zhang, Chunyang ^a   Xi, Hao ^a   Yi, Qing ^b,c   Hou, Jian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Heat shock proteins; Immunotherapy; Multiple myeloma; Vaccine

Indexed keywords

HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 90; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; HSP90AA1 PROTEIN, HUMAN; HSPB1 PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ADOPTIVE IMMUNOTHERAPY; AGED; ANIMAL; BIOSYNTHESIS; CYTOTOXIC T LYMPHOCYTE; DRUG SCREENING; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MOUSE; MULTIPLE MYELOMA; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; SCID MOUSE; TRANSGENIC MOUSE; TUMOR CELL LINE;

AGED; ANIMALS; CELL LINE, TUMOR; FEMALE; HLA-A2 ANTIGEN; HSP27 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MIDDLE AGED; MULTIPLE MYELOMA; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905977473     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12943     Document Type: Article

References (40)

1. Abdi, J., Chen, G. & Chang, H. (2013) Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget, 4, 2186-2207.
2. Albrecht, J., Frey, M., Teschner, D., Carbol, A., Theobald, M., Herr, W. & Distler, E. (2011) IL-21-treated naive CD45RA+ CD8 + T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype. Cancer Immunology Immunotherapy, 60, 235-248.
3. + IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. Journal of Immunology, 168, 6189-6198.
4. Assimon, V.A., Gillies, A.T., Rauch, J.N. & Gestwicki, J.E. (2013) Hsp70 protein complexes as drug targets. Current Pharmaceutical Design, 19, 404-417.
5. Bae, J., Carrasco, R., Lee, A.H., Prabhala, R., Tai, Y.T., Anderson, K.C. & Munshi, N.C. (2011a) Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia, 25, 1610-1619.
6. Bae, J., Tai, Y.T., Anderson, K.C. & Munshi, N.C. (2011b) Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. British Journal of Haematology, 155, 349-361.
7. Bae, J., Smith, R., Daley, J., Mimura, N., Tai, Y.T., Anderson, K.C. & Munshi, N.C. (2012) Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clinical Cancer Research, 18, 4850-4860.
8. van Baren, N., Brasseur, F., Godelaine, D., Hames, G., Ferrant, A., Lehmann, F., Andre, M., Ravoet, C., Doyen, C., Spagnoli, G.C., Bakkus, M., Thielemans, K. & Boon, T. (1999) Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood, 94, 1156-1164.
9. Betts, M.R., Brenchley, J.M., Price, D.A., De Rosa, S.C., Douek, D.C., Roederer, M. & Koup, R.A. (2003) Sensitive and viable identification of antigen-specific CD8 + T cells by a flow cytometric assay for degranulation. Journal of Immunological Methods, 281, 65-78.
10. Bordoni, V., Casetti, R., Capuano, G., De Stefani, B., Piselli, P., Gioia, C., Agrati, C. & Martini, F. (2012) A novel 8-color flow cytometry panel to study activation, maturation and senescence of CD4 and CD8 T lymphocytes in HIV-infected individuals at different stages of disease. International Journal of Immunopathology and Pharmacology, 25, 415-424.
11. Cervantes-Gomez, F., Nimmanapalli, R. & Gandhi, V. (2011) ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells. Journal of Pharmacology and Experimental Therapeutics, 339, 545-554.
12. Chauhan, D., Auclair, D., Robinson, E.K., Hideshima, T., Li, G., Podar, K., Gupta, D., Richardson, P., Schlossman, R.L., Krett, N., Chen, L.B., Munshi, N.C. & Anderson, K.C. (2002) Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene, 21, 1346-1358.
13. Chauhan, D., Li, G., Hideshima, T., Podar, K., Mitsiades, C., Mitsiades, N., Catley, L., Tai, Y.T., Hayashi, T., Shringarpure, R., Burger, R., Munshi, N., Ohtake, Y., Saxena, S. & Anderson, K.C. (2003) Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood, 102, 3379-3386.
14. De Maio, A. (1999) Heat shock proteins: facts, thoughts, and dreams. Shock (Augusta, Ga.), 11, 1-12.
15. De Vos, J., Thykjaer, T., Tarte, K., Ensslen, M., Raynaud, P., Requirand, G., Pellet, F., Pantesco, V., Reme, T., Jourdan, M., Rossi, J.F., Orntoft, T. & Klein, B. (2002) Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene, 21, 6848-6857.
16. Duus, J., Bahar, H.I., Venkataraman, G., Ozpuyan, F., Izban, K.F., Al-Masri, H., Maududi, T., Toor, A. & Alkan, S. (2006) Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leukemia & Lymphoma, 47, 1369-1378.
17. Endemann, M., Bergmeister, H., Bidmon, B., Boehm, M., Csaicsich, D., Malaga-Dieguez, L., Arbeiter, K., Regele, H., Herkner, K. & Aufricht, C. (2007) Evidence for HSP-mediated cytoskeletal stabilization in mesothelial cells during acute experimental peritoneal dialysis. American Journal of Physiology-Renal Physiology, 292, F47-F56.
18. Hart, D.N. (1997) Dendritic cells: unique leukocyte populations which control the primary immune response. Blood, 90, 3245-3287.
19. Hong, S., Li, H., Qian, J., Yang, J., Lu, Y. & Yi, Q. (2012) Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clinical and Experimental Immunology, 170, 167-177.
20. Hufford, M.M., Kim, T.S., Sun, J. & Braciale, T.J. (2011) Antiviral CD8 + T cell effector activities in situ are regulated by target cell type. Journal of Experimental Medicine, 208, 167-180.
21. Jaiswal, M.K., Agrawal, V. & Jaiswal, Y.K. (2013) Lipopolysaccharide drives alternation of heat shock proteins and induces failure of blastocyst implantation in mouse. Biology of Reproduction, 88, 162.
22. Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M.F., Fritz, L.C. & Burrows, F.J. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 425, 407-410.
23. Landowski, T.H., Gleason-Guzman, M.C. & Dalton, W.S. (1997) Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood, 89, 1854-1861.
24. LeBlanc, R., Catley, L.P., Hideshima, T., Lentzsch, S., Mitsiades, C.S., Mitsiades, N., Neuberg, D., Goloubeva, O., Pien, C.S., Adams, J., Gupta, D., Richardson, P.G., Munshi, N.C. & Anderson, K.C. (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research, 62, 4996-5000.
25. Lin, H., Kolosenko, I., Bjorklund, A.C., Protsyuk, D., Osterborg, A., Grander, D. & Tamm, K.P. (2013) An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma. Experimental Cell Research, 319, 600-611.
26. Mellqvist, U.H., Gimsing, P., Hjertner, O., Lenhoff, S., Laane, E., Remes, K., Steingrimsdottir, H., Abildgaard, N., Ahlberg, L., Blimark, C., Dahl, I.M., Forsberg, K., Gedde-Dahl, T., Gregersen, H., Gruber, A., Guldbrandsen, N., Haukas, E., Carlson, K., Kvam, A.K., Nahi, H., Lindas, R., Andersen, N.F., Turesson, I., Waage, A. & Westin, J. (2013) Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood, 121, 4647-4654.
27. Nalesnik, M.A. (2013) Plasma cell tumors in transplant patients. Blood, 121, 1247-1249.
28. Pellat-Deceunynck, C., Mellerin, M.P., Labarriere, N., Jego, G., Moreau-Aubry, A., Harousseau, J.L., Jotereau, F. & Bataille, R. (2000) The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. European Journal of Immunology, 30, 803-809.
29. Qian, J., Wang, S., Yang, J., Xie, J., Lin, P., Freeman, M.E. 3rd & Yi, Q. (2005) Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96. Clinical Cancer Research, 11, 8808-8815.
30. Qian, J., Xie, J., Hong, S., Yang, J., Zhang, L., Han, X., Wang, M., Zhan, F., Shaughnessy, J.D. Jr, Epstein, J., Kwak, L.W. & Yi, Q. (2007) Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood, 110, 1587-1594.
31. Qian, J., Hong, S., Wang, S., Zhang, L., Sun, L., Wang, M., Yang, J., Kwak, L.W., Hou, J. & Yi, Q. (2009) Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. Blood, 114, 3880-3889.
32. Qu, X., Du, J., Zhang, C., Fu, W., Xi, H., Zou, J. & Hou, J. (2012) Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6. PLoS ONE, 7, e32215.
33. Rollig, C., Schmidt, C., Bornhauser, M., Ehninger, G., Schmitz, M. & Auffermann-Gretzinger, S. (2011) Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. Journal of Immunotherapy (Hagerstown, Md.: 1997), 34, 100-106.
34. Schreurs, M.W., Eggert, A.A., de Boer, A.J., Vissers, J.L., van Hall, T., Offringa, R., Figdor, C.G. & Adema, G.J. (2000) Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Research, 60, 6995-7001.
35. Sellner, L., Heiss, C., Benner, A., Raab, M.S., Hillengass, J., Hose, D., Lehners, N., Egerer, G., Ho, A.D., Goldschmidt, H. & Neben, K. (2013) Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. Cancer, 119, 2438-2446.
36. Tangri, S., Ishioka, G.Y., Huang, X., Sidney, J., Southwood, S., Fikes, J. & Sette, A. (2001) Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. Journal of Experimental Medicine, 194, 833-846.
37. Tosi, P., Tomassetti, S., Merli, A. & Polli, V. (2013) Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions. Therapeutic Advances in Hematology, 4, 37-41.
38. Treon, S.P., Mollick, J.A., Urashima, M., Teoh, G., Chauhan, D., Ogata, A., Raje, N., Hilgers, J.H., Nadler, L., Belch, A.R., Pilarski, L.M. & Anderson, K.C. (1999) Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood, 93, 1287-1298.
39. Tyler, E.M., Jungbluth, A.A., O'Reilly, R.J. & Koehne, G. (2013) WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood, 121, 308-317.
40. Vermijlen, D., Froelich, C.J., Luo, D., Suarez-Huerta, N., Robaye, B. & Wisse, E. (2001) Perforin and granzyme B induce apoptosis in FasL-resistant colon carcinoma cells. Cancer Immunology Immunotherapy, 50, 212-217.